CA2902905A1 - Modified toxins - Google Patents

Modified toxins Download PDF

Info

Publication number
CA2902905A1
CA2902905A1 CA2902905A CA2902905A CA2902905A1 CA 2902905 A1 CA2902905 A1 CA 2902905A1 CA 2902905 A CA2902905 A CA 2902905A CA 2902905 A CA2902905 A CA 2902905A CA 2902905 A1 CA2902905 A1 CA 2902905A1
Authority
CA
Canada
Prior art keywords
amino acid
modified
diphtheria toxin
cell
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2902905A
Other languages
English (en)
French (fr)
Inventor
Claude Geoffrey Davis
Deepshikha Datta
Matthew Paul Baker
Alyson Jane Rust
Simon Keen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ANGELICA THERAPEUTICS Inc
Original Assignee
ANGELICA THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ANGELICA THERAPEUTICS Inc filed Critical ANGELICA THERAPEUTICS Inc
Publication of CA2902905A1 publication Critical patent/CA2902905A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2902905A 2013-03-15 2014-03-11 Modified toxins Abandoned CA2902905A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361799910P 2013-03-15 2013-03-15
US61/799,910 2013-03-15
PCT/US2014/023761 WO2014150600A2 (en) 2013-03-15 2014-03-11 Modified toxins

Publications (1)

Publication Number Publication Date
CA2902905A1 true CA2902905A1 (en) 2014-09-25

Family

ID=51581612

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2902905A Abandoned CA2902905A1 (en) 2013-03-15 2014-03-11 Modified toxins

Country Status (6)

Country Link
US (1) US10059750B2 (enExample)
EP (1) EP2968450A4 (enExample)
JP (1) JP2016519651A (enExample)
CA (1) CA2902905A1 (enExample)
HK (1) HK1220376A1 (enExample)
WO (1) WO2014150600A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc MODIFIED TOXINS
US10642391B2 (en) * 2015-06-19 2020-05-05 Lg Electronics Inc. Touch panel and display device
JP7299021B2 (ja) * 2015-09-11 2023-06-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 生体関連の直交性サイトカイン／受容体ペア
US10899829B2 (en) 2016-02-23 2021-01-26 Indiana University Research And Technology Corporation Emapii neutralizing antibody limits influenza A virus (IAV)-induced lung injury
KR20240115933A (ko) * 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
CN110325205B (zh) * 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11219680B2 (en) 2017-02-24 2022-01-11 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment B as a carrier
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019212846A1 (en) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
JP7397000B2 (ja) 2018-04-30 2023-12-12 メルク・シャープ・アンド・ドーム・エルエルシー 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法
WO2019212842A1 (en) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
CN111944036B (zh) 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
EP4143329A4 (en) * 2020-04-28 2024-10-16 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4830962A (en) 1984-02-09 1989-05-16 Cetus Corporation Recombinant diphtheria toxin fragments
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US5792458A (en) 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
KR900700134A (ko) 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
SG88714A1 (en) 1989-11-06 2002-05-21 Cell Genesys Inc Production of proteins using homologous recombination
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
FI923915A7 (fi) 1990-03-02 1992-09-01 Boston Medical Ct Corp Paranettuja kimeerisiä toksiineja
WO1992006117A1 (en) 1990-09-28 1992-04-16 Seragen, Inc. Inhibiting unwanted immune responses
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5695983A (en) 1990-12-18 1997-12-09 The General Hospital Corporation Salmonella vaccines
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
JP3506431B2 (ja) 1992-05-06 2004-03-15 プレジデント アンド フェローズ オブ ハーバード カレッジ ジフテリア毒素受容体結合領域
DK0652758T3 (da) 1992-06-18 2000-05-08 Harvard College Diferitoxin-vacciner
US5856122A (en) 1993-08-24 1999-01-05 University Of Alberta Modification of pertussis toxin
EP0746613B1 (en) 1994-03-08 2006-05-24 Memorial Sloan-Kettering Cancer Center Recombinant humanized anti-fb5 antibodies
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
DE4430721A1 (de) 1994-08-30 1996-03-07 Hoechst Ag Autoglanztrocknungsmittel
US5843462A (en) 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
AU1461497A (en) * 1996-12-09 1998-07-03 Genencor International, Inc. Proteins Having Increased Stability
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US5976806A (en) 1997-06-25 1999-11-02 Pioneer Hi-Bred International, Inc. DNA ligase assay
US6835550B1 (en) 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6566500B1 (en) 1999-03-30 2003-05-20 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinaceous compounds
US6960652B2 (en) 1999-03-30 2005-11-01 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinaceous compounds
AU7636800A (en) 1999-10-04 2001-05-10 Twinstrand Therapeutics Inc. Improved ricin-like toxins for treatment of cancer
US7368532B2 (en) 1999-12-02 2008-05-06 Syntaxin Limited Constructs for delivery of therapeutic agents to neuronal cells
EP1252183B1 (en) 1999-12-02 2006-05-24 Thromb-X N.V. Method for reducing the immunogenicity of staphylokinase by elimination of t-cell epitopes
US20060018885A1 (en) 2000-11-14 2006-01-26 Ildstad Suzanne T Methods for increasing HSC graft efficiency
US20040256304A1 (en) 2001-01-19 2004-12-23 Perry Carlos V. Recirculating filter
WO2002062842A1 (en) 2001-02-06 2002-08-15 Merck Patent Gmbh Modified keratinocyte growth factor (kgf) with reduced immunogenicity
KR20030074785A (ko) 2001-02-06 2003-09-19 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질 과립구 집락 자극인자(ｇ-ｃｓｆ)
WO2002062832A2 (en) 2001-02-06 2002-08-15 Merck Patent Gmbh Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
HUP0400698A3 (en) 2001-02-06 2006-01-30 Merck Patent Gmbh Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity
CN1491232A (zh) 2001-02-06 2004-04-21 Ĭ��ר�����޹�˾ 免疫原性减弱的经修饰肥胖蛋白
JP2004522445A (ja) 2001-02-06 2004-07-29 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 低減された免疫原性を有する修飾されたエリスロポエチン（ｅｐｏ）
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
JP4279554B2 (ja) 2001-02-19 2009-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔ細胞エピトープの識別方法および低減された免疫原性を有する分子の製造方法
PL362324A1 (en) 2001-02-19 2004-10-18 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
WO2002066058A1 (en) 2001-02-19 2002-08-29 Merck Patent Gmbh Modified anti-egfr antibodies with reduced immunogenicity
CA2439168A1 (en) 2001-02-26 2002-09-06 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified thrombopoietin with reduced immunogenicity
EP1379555A2 (en) 2001-03-02 2004-01-14 MERCK PATENT GmbH Modified interferon alpha with reduced immunogenicity
HUP0303310A2 (hu) 2001-03-02 2003-12-29 Merck Patent Gmbh Csökkentett immunogenitású módosított ciliáris neurotrofikus faktor (CNTF)
RU2003129062A (ru) 2001-03-08 2005-04-10 Мерк Патент ГмбХ (DE) Модифицированный протамин с уменьшенной иммуногенностью
WO2002070548A2 (en) 2001-03-08 2002-09-12 Merck Patent Gmbh Modified human granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity
PL362870A1 (en) 2001-03-15 2004-11-02 Merck Patent Gmbh Modified interferon beta with reduced immunogenicity
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
CA2447695C (en) 2001-06-01 2015-02-24 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2003000193A2 (en) 2001-06-21 2003-01-03 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
CN102206276B (zh) 2001-06-26 2013-07-17 艾根生物医学有限公司 血纤维蛋白d-二聚体片段特异性的、来源于dd-3b6/22的人源化抗体
CA2453406A1 (en) 2001-07-13 2003-01-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Methods for reducing immunogenicity of polypeptides
CA2457429A1 (en) 2001-09-04 2003-03-13 Francis J. Carr Modified factor ix
HUP0402334A3 (en) 2001-09-04 2007-03-28 Merck Patent Gmbh Modified human growth hormone
AU2002351957B2 (en) 2001-11-12 2009-09-03 Merck Patent Gmbh Modified anti-TNF alpha antibody
CA2468501A1 (en) 2001-11-29 2003-06-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung T-cell epitodes in carboxypeptidase g2
PL371202A1 (en) 2002-04-09 2005-06-13 Merck Patent Gmbh Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
MXPA04010061A (es) 2002-04-18 2004-12-13 Merck Patent Gmbh Factor viii modificado.
US20050181459A1 (en) 2002-06-11 2005-08-18 Matthew Baker Method for mapping and eliminating T cell epitopes
US20040018568A1 (en) 2002-07-23 2004-01-29 Subhashis Banerjee Methods for detecting deantigenized T cell epitopes and uses thereof
RU2005106841A (ru) 2002-08-09 2005-10-27 Мерк Патент ГмбХ (DE) Эпитопы т-клеток в эритропоэтине
US20050240009A1 (en) 2002-08-21 2005-10-27 Carr Francis J T-cell epitopes in staphylococcal enterotoxin b
AU2003302986A1 (en) 2002-12-13 2004-07-09 Aurelium Biopharma Inc. Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
AU2004204942A1 (en) 2003-01-08 2004-07-29 Xencor, Inc Novel proteins with altered immunogenicity
NZ542988A (en) 2003-04-23 2008-07-31 Medarex Inc Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies
WO2004113386A2 (en) 2003-06-26 2004-12-29 Merck Patent Gmbh Modified hirudin proteins and t-cell epitopes in hirudin
EP1636261B1 (en) 2003-06-26 2007-08-01 MERCK PATENT GmbH Thrombopoietin proteins with improved properties
AR045614A1 (es) 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
US20050176028A1 (en) 2003-10-16 2005-08-11 Robert Hofmeister Deimmunized binding molecules to CD3
EP1694706B1 (en) 2003-11-01 2012-04-04 Merck Patent GmbH Modified anti-cd52 antibody
US7431720B2 (en) 2003-11-25 2008-10-07 Ethicon, Inc. Multi-function clamping device with stapler and ablation heads
US7585942B2 (en) 2003-11-25 2009-09-08 Anjin Corporation Diphtheria toxin variant
US20050153872A1 (en) 2004-01-12 2005-07-14 Xiao-Qing Qiu Methods and compositions for the treatment of infection
US20060228404A1 (en) 2004-03-04 2006-10-12 Anderson Daniel G Compositions and methods for treatment of hypertrophic tissues
CA2560278C (en) 2004-03-19 2012-11-20 Matthew Baker Modified bouganin proteins, cytotoxins and methods and uses thereof
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
US20060165687A1 (en) 2004-10-19 2006-07-27 Duke University Vaccine adjuvant
WO2006044864A2 (en) 2004-10-19 2006-04-27 Duke University Vaccine adjuvant
CN1314806C (zh) 2005-01-14 2007-05-09 四川大学 小型化抗eb病毒肿瘤多肽及其应用与制备方法
US20060270600A1 (en) 2005-05-26 2006-11-30 Eisuke Mekada Anti-cancer agents
US20060269514A1 (en) 2005-05-27 2006-11-30 Abdul-Rahman Jazieh Methods and compositions for the modulation of immune responses and cancer diseases
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
US20070250652A1 (en) 2006-04-24 2007-10-25 Atmel Corporation High speed dual-wire communications device requiring no passive pullup components
EP2046375B1 (en) 2006-07-20 2017-04-05 The General Hospital Corporation Methods and compositions for the selective activation of protoxins through combinatorial targeting
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
US20090010966A1 (en) 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
EP2268297A4 (en) 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc MODIFIED TOXINS

Also Published As

Publication number Publication date
WO2014150600A2 (en) 2014-09-25
US10059750B2 (en) 2018-08-28
EP2968450A2 (en) 2016-01-20
WO2014150600A3 (en) 2015-05-28
JP2016519651A (ja) 2016-07-07
EP2968450A4 (en) 2016-10-26
US20160009768A1 (en) 2016-01-14
HK1220376A1 (zh) 2017-05-05
WO2014150600A8 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
US10059750B2 (en) Modified toxins
US8470314B2 (en) Modified toxins
EP2167528B1 (en) Modified toxins
AU2005270336B2 (en) Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
US20160068577A1 (en) Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
JP4175489B2 (ja) 改変型超抗原と標的探索化合物との結合体及び該結合体の使用
CA3058427C (en) Alt-803 in combination with anti-cd38 antibody for cancer therapies
CN101712721A (zh) T细胞受体融合物及共轭物以及其使用方法
JP2004507264A (ja) インターロイキン１３のアミノ酸置換変異体
PT1093465E (pt) ''processo para produzir ou intensificar uma resposta de células t contra uma célula alvo, utilizando um complexo compreendendo uma molécula hla de classe i e meios de ligação''
AU2018308982A1 (en) Methods and compositions for the treatment of cancer
CN116836260A (zh) 一种识别mage-a4的t细胞受体及其编码序列和应用
US20210147545A1 (en) Immunotoxins for use in treating cancer
HK1143168B (en) Modified toxins
HK1143168A (en) Modified toxins
HK1263031A1 (zh) 去免疫的治疗性组合物和方法
TW201531485A (zh) 融合蛋白及其製造方法、及運用融合蛋白輸送抗原性胜肽至內質網的方法

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200311